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Background: Severe and fatal malaria are associated with dysregulated host inflammatory responses to infection.
Chitinase 3-like 1 (CHI3L1) is a secreted glycoprotein implicated in regulating immune responses. Expression and
function of CHI3L1 in malaria infection were investigated.
Methods: Plasma levels of CHI3L1 were quantified in a case–control study of Ugandan children presenting with
Plasmodium falciparum malaria. CHI3L1 levels were compared in children with uncomplicated malaria (UM; n = 53),
severe malarial anaemia (SMA; n = 59) and cerebral malaria (CM; n = 44) using the Kruskall Wallis-test, and evaluated
for utility in predicting fatal (n = 23) versus non-fatal (n = 80) outcomes in severe disease using the Mann Whitney U
test, receiver operating characteristic curves, and combinatorial analysis. Co-culture of P. falciparum with human
peripheral blood mononuclear cells and the Plasmodium berghei ANKA experimental model of cerebral malaria were
used to examine the role of CHI3L1 in severe malaria.
Results: In children presenting with falciparum malaria, CHI3L1 levels were increased in SMA and CM versus UM
(p < 0.001). Among severe malaria cases, CHI3L1 levels at presentation predicted subsequent death (area under
receiver operating characteristic curve 0.84 [95% CI 0.76-0.92]) and in combination with other host biomarkers, predicted
mortality with high sensitivity (100% [85.7-100]) and specificity (81.3% [71.3-88.3]). Plasmodium falciparum stimulated
CHI3L1 production by human peripheral blood mononuclear cells in vitro. CHI3L1 was increased in plasma and
brain tissue in experimental cerebral malaria, but targeted Chi3l1 deletion did not alter cytokine production or
survival in this model.
Conclusions: These data suggest that plasma CHI3L1 measured at presentation correlates with malaria severity
and predicts outcome in paediatric SMA and CM, but do not support a causal role for CHI3L1 in cerebral malaria
pathobiology in the model tested.
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Malaria causes an estimated 450 million infections and 1.24
million deaths annually [1,2]. Most deaths are attributable
to severe Plasmodium falciparum infection in African chil-
dren. The two major severe malaria syndromes are cerebral
malaria (CM), which presents as coma and/or seizures, and
severe malarial anaemia (SMA). Case fatality rates for CM
and SMA are 18% and 10%, respectively, despite optimal
anti-malarial treatment [3]. An improved understanding of
pathogenesis is required to develop adjunctive therapies, as
well as prognostic tools to guide triage and appropriate al-
location of limited health care resources.
While the sequestration of parasitized erythrocytes is
central to severe malaria pathogenesis, disease progression
is also influenced by host responses to infection, including
inflammation. A robust TH1 response is critical for control
of parasite replication, but severe disease is associated with
dysregulated inflammation. Children with CM have ele-
vated serum/plasma TH1 cytokines compared to uncompli-
cated cases [4,5], and increased immune cell accumulation
and cytokine transcription in the brain [6,7]. These local
and systemic responses are thought to contribute to CM
by activating brain endothelium, leading to upregulated cell
adhesion molecules, parasite sequestration, and micro-
vascular obstruction [8]. Murine models of CM – which
replicate many but not all aspects of human CM – lend
causal support to these mechanisms [9-11]. In SMA, rela-
tive increases in TH1 cytokines [12,13] may contribute to
anaemia by suppressing erythropoiesis and enhancing ery-
throphagocytosis [14,15]. At the molecular level, pattern
recognition receptors (e.g., Toll-like receptors (TLRs) [16])
and cytokines (e.g., IFN-γ [17]) have been implicated in
these inflammatory responses, but the pathways remain
ill-defined.
Chitinase 3-like 1 (CHI3L1) is a 40 kDa secreted glyco-
protein from the highly conserved 18 glycosyl hydrolase
family. CHI3L1 is structurally similar to chitinases and
can bind chitin, but lacks chitinase activity due to altered
active site residues [18,19]. It is secreted by a variety of cell
types, including macrophages, neutrophils, fibroblasts, as-
trocytes, and tumour cells [20]. Expression is induced by
stimuli such as cytokines, radiation, and hypoxia [21-23].
CHI3L1 levels are increased in chronic inflammatory con-
ditions and acute infections such as pneumonia, meningi-
tis, and sepsis [24-26], and often correlate with disease
severity and prognosis [20].
CHI3L1 has been implicated in diverse biological pro-
cesses, including tissue remodelling, angiogenesis, and cell
survival (reviewed in [20]). Of relevance to malaria, CHI3L1
has been shown to modulate immune responses. CHI3L1
contributed to induction and propagation of pathological
TH2 responses in a murine asthma model. Chi3l1
−/− mice
had decreased lung inflammation, secondary to increased
apoptosis of immune cells [27]. Conversely, Chi3l1 deletionworsened outcome in a murine model of Streptococcus
pneumonia, with increased bacterial burden, lung in-
flammation, TH1 cytokines, and death. This was attrib-
uted to enhanced inflammasome activation and
macrophage pyroptosis, leading to poor infection con-
trol [28]. Thus, CHI3L1 appears to skew immune re-
sponses towards a TH2 profile, and depending on
underlying disease mechanisms, may promote or pro-
tect against immunopathology.
Given the association of severe malaria with excessive
TH1 inflammatory responses, it is reasonable to hypothesize
that CHI3L1 levels would be increased in severe malaria in-
fection, and would protect against immunopathology in ex-
perimental CM (ECM). This report demonstrates that
plasma CHI3L1 levels in Ugandan children presenting with
P. falciparum malaria correlated with disease severity and
predicted fatal outcome. Exposure of human immune cells
to P. falciparum parasitized erythrocytes induced CHI3L1
expression, and plasma and brain CHI3L1 were increased
in the Plasmodium berghei ANKA model of ECM. How-
ever, targeted Chi3l1 deletion did not affect inflammatory
parameters or survival in this model.Methods
Study population and ethics statements
The study population has been previously described [29].
Briefly, this case–control study is nested within a prospect-
ive observational case–control study at Mulago Hospital in
Kampala, Uganda [30]. In the larger study, paediatric pa-
tients (six months to 12 years old) presenting with fever
and microscopy-confirmed P. falciparum infection were eli-
gible for enrollment. Cases were defined as children who
died and/or fulfilled World Health Organization criteria for
CM, SMA, hypoxia, or lactic acidosis [31], while controls
were age-matched children lacking these criteria (“uncom-
plicated malaria”, UM). Exclusion criteria included severe
malnutrition, HIV co-infection, sickle cell trait/disease, ab-
sence of adequate consent, or death prior to collection of
any laboratory specimens. After informed consent, clinical
and demographic data and venous blood samples were col-
lected. Citrate plasma was aliquoted and stored at −20°C
until testing. Thin blood smears obtained at presentation
were reviewed at a reference parasitology laboratory by two
independent experts to determine parasite density. For the
biomarker analysis, CM and SMA inpatients (cases) and
UM outpatients (controls) were selected from the larger
study based on availability of previously unthawed plasma.
Ethical approval for the study was obtained from the
Mulago Hospital Research Ethics Committee, Makerere
University Faculty of Medicine Research Ethics Committee,
Uganda National Council for Science & Technology, and
the University Health Network. Written informed consent
was obtained from parents/guardians before enrollment.
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Plasma samples were assayed using the CHI3L1 Duoset
ELISA kit (R&D Systems) according to the manufacturer’s
instructions with the following changes: assays were per-
formed in 50 μL/well; plasma samples were incubated
overnight at 4°C; and ELISAs were developed using Extra-
vidin®-Alkaline Phosphatase (Sigma, 1:1000, 45 min)
followed by addition of p-Nitrophenyl phosphate substrate
(Sigma) and optical density readings at 405 nm.
Plasmodium falciparum culture
Plasmodium falciparum (ITG strain) was cultured as pre-
viously described [32]. Cultures were treated with
Mycoplasma-Removal Agent (MP Biochemicals), con-
firmed to be mycoplasma-free (MycoAlert Mycoplasma
Detection Kit, Lonza), and synchronized by alanine treat-
ment [33]. Mature-stage cultures were used in assays.
Peripheral blood mononuclear cell (PBMC) isolation
and stimulation
Human PBMCs were isolated from venous blood of
healthy volunteers by gradient centrifugation using Ficoll-
Paque (GE Healthcare). PBMCs were suspended in RPMI
1640 with 10% foetal bovine serum and gentamicin
(Gibco-Invitrogen) and incubated with medium alone,
LPS (10 ng/mL), P. falciparum parasitized erythrocytes
(3:1), or uninfected erythrocytes. Conditions were per-
formed in duplicate or triplicate. Cell-free supernatants
were collected and analysed by CHI3L1 ELISA (R&D Sys-
tems). Cells were gently scraped and cDNA was prepared
as described below.
Quantitation of human CHI3L1 mRNA
Total RNA was purified from PBMCs using the RNeasy
kit (Qiagen). Following DNase treatment (Fermentas),
mRNA was converted to cDNA (iScript, Bio-Rad La-
boratories) and subjected to quantitative real-time PCR
analysis for CHI3L1 mRNA levels (forward primer: 5’-T
GCCCTTGACCGCTCCTCTGTACC-3’; reverse pri-
mer: 5’-GAGCGTCACATCATTCCACTC-3’; standard
cycling protocol). Copy number was interpolated from a
standard curve of genomic DNA and normalized to the
geometric mean of housekeeping genes Hbms, Ywhaz,
and B2m.
Experimental cerebral malaria model
Chi3l1−/− mice on a C57BL/6 background [27] were bred
with wild-type C57BL/6 mice (The Jackson Laboratory,
Maine, USA) to generate heterozygotes, which were then
bred to produce Chi3l1−/− mice and wild-type littermates.
Frozen stocks of P. berghei (strain ANKA, MRA-311,
MR4 ATCC, Virginia, USA) were passaged through
C57BL/6 mice to obtain infected blood. Female mice (6–
10 weeks old) were administered 1×106 infected red bloodcells by intraperitoneal injection. Tail vein blood smears
were stained with Hema-3 Stain Set (Fisher Scientific) to
determine parasitaemia. Mice were euthanized upon de-
velopment of neurological signs, severe dehydration, or
lethargy. Animal protocols were approved by the Univer-
sity of Toronto Animal Care Committee and all animal
work was performed in compliance with university institu-
tional guidelines.
Plasma protein determination in ECM model
Mice were euthanized by inhaled CO2 at various times
during infection, blood was obtained by cardiac puncture,
and plasma was assayed by mouse CHI3L1 ELISA (R&D
Systems). Saphenous vein blood was collected on Day 0
and 4 of infection and cytokines were measured in plasma
using Cytometric Bead Array (Mouse Inflammation Kit,
Becton Dickinson).Quantification of brain CHI3L1 transcripts in ECM model
Plasmodium berghei ANKA-infected mice were eutha-
nized, brains were snap-frozen in liquid nitrogen and
stored at −80°C. RNA extraction was performed as fol-
lows: samples were homogenized in Trizol (Invitrogen),
briefly incubated at room temperature, and mixed with
chloroform. The aqueous phase was collected and RNA
was precipitated with isopropanol at room temperature.
RNA pellets were washed with 75% ethanol, dried, and
dissolved in water. DNase treatment, conversion to
cDNA, and qRT-PCR were performed (CHI3L1 forward
primer: 5’-GTACAAGCTGGTCTGCTACTTC-3’; Re-
verse primer: 5’-ATGTGCTAAGCATGTTGTCGC-3’).
Copy number was interpolated from a genomic DNA
standard curve and normalized to the geometric mean
of Gapdh, Ywhaz, Hrpt.Statistical analysis
Analyses were performed using GraphPad Prism v4.03
(San Diego, CA), IBM SPSS v22.0 (Armonk, NY), and
MedCalc Statistical Software v13.0.6 (Ostend, Belgium).
Differences between groups were assessed using the
Mann–Whitney U test or Kruskal-Wallis test with Dunn’s
post-tests. Survival curves were compared using the log-
rank test. Receiver operating characteristic (ROC) curves
were generated and compared using the non-parametric
method of Delong et. al. Biomarker cut-points were deter-
mined using the Youden index (J =max[sensitivity + speci-
ficity – 1]). CHI3L1 was combined with other biomarkers
identified in a previous publication [29]: angiopoietin-2,
CXCL10 (IP-10), procalcitonin, soluble ICAM-1, soluble
FLT-1, and soluble TREM-1. Positive and negative predict-
ive values were calculated using the reported case fatality
rate of 5.7% for CM and SMA at Mulago Hospital [34].
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Plasma CHI3L1 is elevated in children with severe versus
uncomplicated malaria
To determine whether CHI3L1 correlates with disease
severity in human malaria, plasma levels of CHI3L1
were compared among groups of Ugandan children pre-
senting to hospital with P. falciparum infection: uncom-
plicated malaria (UM; n = 53), CM (n = 44), and SMA
(n = 59) [29]. Demographic and clinical characteristics
are shown in Table 1. Groups were comparable, except
that children with SMA were younger with longer dur-
ation of illness prior to presentation and lower parasit-
aemia. At time of presentation to hospital, plasma CHI3L1
was significantly higher in children with CM and SMA
compared to uncomplicated malaria (p < 0.001; Figure 1A),
indicating that CHI3L1 levels reflect disease severity in
malaria infection.
CHI3L1 levels predict fatality in severe malaria
Next, it was assessed whether CHI3L1 could prognosti-
cate outcome among children with severe malaria, which
could facilitate clinical triage and resource allocation.
CHI3L1 levels were higher among children with CM
and SMA who subsequently went on to die of their in-
fection, compared to survivors in their respective groups
(p < 0.01; Figure 1B). As CHI3L1 values were similar be-
tween CM and SMA, and there is often clinical overlap
between syndromes, all children with severe disease
were combined, with similar results (Figure 1B; Table 1).
This grouping was used for further analysis. CHI3L1
showed good discriminatory ability between fatalities
and survivors in ROC curve analysis (Figure 1C; area
under ROC curve [AUROCC] 0.84, 95% CI 0.76-0.92).
This was comparable to the best-performing host bio-
markers in previous reports [29,35,36]. CHI3L1 was also
superior to parasitaemia (Figure 1C; AUROCC 0.66, 95%
CI 0.56-0.75, difference between AUROCCs 0.181, 95%
CI 0.037-0.33, p = 0.014), which is often used to evaluate
severity in clinical settings.
To quantify the ability of CHI3L1 to predict outcome in
severe malaria, a numerical cut-point was selected based on
the Youden Index (see Methods Section). A cut-point of
179.1 ng/mL had high sensitivity (91.3%) but low specificity
(67.5%) for predicting mortality (Table 2). To improve upon
the accuracy of CHI3L1, CHI3L1 was combined with other
biomarkers that were previously found to predict outcome
in this sample [29]. For all possible two- or three-marker
combinations involving CHI3L1, an additive scoring system
was applied to each patient: one point was assigned for
each biomarker value above its respective cut-point, and
these were summed. Scores were evaluated for predictive
ability. This analysis yielded combinations with >90% sensi-
tivity and >80% specificity for predicting mortality, with
negative predictive values >99% (Table 2). These resultsindicate that plasma CHI3L1, in combination with other
biomarkers, may have clinical utility for prognosis in chil-
dren with severe malaria.
Plasmodium falciparum stimulates CHI3L1 production by
human immune cells
Next, potential sources of CHI3L1 during malaria infec-
tion were examined. As malaria is a blood-borne infection,
P. falciparum-infected erythrocytes were co-cultured with
human peripheral blood mononuclear cells (PBMCs). As a
positive control, LPS stimulated CHI3L1 transcription
(Figure 2A) and protein secretion (Figure 2B) [37]. Com-
pared to incubation with uninfected red blood cells, ex-
posure to P. falciparum-infected erythrocytes for 24 hours
induced an average 2-fold increase in CHI3L1 transcrip-
tion (Figure 2A), and also significantly increased secretion
of CHI3L1 protein (Figure 2B).
CHI3L1 levels are increased in experimental cerebral
malaria, but outcome is unaffected by Chi3l1 deletion
The regulation and role of CHI3L1 in vivo were then in-
vestigated using a murine model of CM. Infection of
C57BL/6 mice with P. berghei strain ANKA produces a
neurological syndrome similar to CM, characterized by
paralysis, ataxia, convulsions, and death between days 6–
12 [11]. This model recapitulates several features of brain
histopathology in human CM, including ring haemor-
rhages, activated endothelium with vascular leak, and
monocyte and parasite accumulation [38,39]. There are
some differences between human CM and ECM: in ECM,
there is greater immune cell sequestration and cerebral
oedema, and less PE sequestration. However, having estab-
lished a clinically relevant role for CHI3L1 as a marker of
disease severity and death in human severe malaria, this
model provides a rational approach to examine mechan-
ism and causality of this pathway in the pathobiology of
severe disease that would be problematic to investigate
directly in humans.
Plasma CHI3L1 was increased in mice on Days 5 and
7 following P. berghei infection (Figure 3A). Using quan-
titative real-time PCR, Chi3l1 mRNA expression in the
brain was significantly elevated on Day 5 compared to
uninfected mice (Figure 3B). To assess whether these el-
evations in CHI3L1 correspond to a functional role in
ECM, Chi3l1−/− mice and their wild-type littermate con-
trols were infected with P. berghei. There were no differ-
ences between wild-type mice and Chi3l1−/− mice in terms
of survival (Figure 3C; p = 0.13 by log-rank test), parasit-
aemia (Figure 3D), or plasma levels of pro-inflammatory
TH1 (TNF, IFN-γ) or anti-inflammatory (IL-10) cytokines
(Figure 3E). Thus, while local and systemic CHI3L1 levels
increase in ECM-susceptible mice during P. berghei infec-
tion, CHI3L1 does not appear to affect immune responses
or outcome in this model.
Table 1 Demographic and clinical characteristics of study participants presenting with uncomplicated and severe malariaa
Characteristic UMb (n = 53) CMc (n = 44) SMA (n = 59) Pooled severe malaria
Survivors (n = 80) Fatalities (n = 23)
Gender (% female) 45.3 52.3 49.2 46.3 65.2§§
Age (years) 4.4 (2.1, 8.1) 3.0 (1.5, 4.3) 1.3 (0.9, 2.0)***### 1.6 (1.0, 3.1) 1.9 (1.2, 3.3)
Days reported ill prior to presentation 3 (2, 4) 3 (2, 4) 4 (3, 5)***# 3 (3, 4) 3 (2, 7)
Parasitaemia (parasites/μL) 3.8 × 104 (1.6 × 104, 1.2 × 105) 9.8 × 104 (1.5 × 104, 2.7 × 105) 2.6 × 104 (7.4 × 103, 1.2 × 105)# 3.7 × 104 (7.5 × 103, 1.5 × 105) 1.6 × 105 (2.2 × 104, 3.9 × 105)§
Fatal cases 0 14 9 0 23
aTable reproduced from the previous study of this population (published in open access journal) [29]. Variables are presented as median (interquartile range). Groups were compared using the Mann Whitney U test or
Kruskal-Wallis test with Dunn’s post-hoc tests (continuous variables) or Chi-square test (categorical variables). bUM, uncomplicated malaria; CM, cerebral malaria; SMA, severe malaria anaemia. c6 children with concur-
rent CM and SMA were included in the CM group. 5 children with SMA exhibited decreased consciousness but did not meet criteria for CM. ***p < 0.001 CM or SMA vs. UM. #p < 0.05, ###p < 0.001 SMA vs. CM. §p <

















Figure 1 Plasma CHI3L1 levels are increased in children with
severe malaria and are predictive of outcome. (A) CHI3L1 was
measured by ELISA in the plasma of Ugandan children presenting to
Mulago Hospital with uncomplicated malaria (UM, n = 53), cerebral
malaria (CM, n = 44), and severe malarial anaemia (SMA, n = 59). (B)
CM and SMA patients were analyzed based on the outcome of
infection (i.e., survival versus fatality). CM and SMA were examined
separately (left side), then pooled together (right side) for further
analysis. Data are presented as dot plots with medians. **p < 0.01
and ***p < 0.001, Kruskal-Wallis test with Dunn’s post-hoc tests. (C)
Receiver operating characteristic (ROC) curve analysis to assess the
utility of CHI3L1 for predicting outcome of infection. Area under the
curve for CHI3L1 is 0.84 (95% CI 0.76-0.92). Parasitaemia (often used
clinically for prognosis) is shown for comparison with area under the
curve 0.66 (95% CI 0.56-0.75).
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This study represents the first investigation into the regula-
tion and role of CHI3L1 in malaria infection. Plasma
CHI3L1 was elevated in Ugandan children with CM and
SMA compared to uncomplicated malaria. Moreover,
CHI3L1 levels at presentation predicted mortality in severe
disease, particularly when combined with other host bio-
markers. These data indicate that CHI3L1 may have clin-
ical utility as a prognostic test component. Using model
systems, it was found that malaria parasites stimulated
CHI3L1 production by human immune cells in vitro, and
plasma and brain CHI3L1 increased during ECM. How-
ever, ECM-susceptible mice and Chi3l1−/− littermates did
not show differences in terms of inflammatory cytokines or
survival, suggesting that CHI3L1 does not critically con-
tribute to ECM pathogenesis in this model.
Consistent with the original hypothesis, plasma
CHI3L1 levels were associated with disease severity in
malaria infection. Inflammation is a known inducer of
CHI3L1, and a well-established feature of severe mal-
aria. Although CM and SMA are often considered to
have distinct pathophysiological mechanisms, excessive
TH1 inflammatory responses are common to both syn-
dromes [4,5,12,13]. Another trigger for CHI3L1 upregu-
lation is hypoxia, which may also be shared between
CM and SMA, albeit for different reasons (microvascu-
lar obstruction and decreased oxygen carrying capacity,
respectively). Thus, it is reasonable that CHI3L1 would
be similarly elevated in both syndromes, and further in-
creased in children with pathology severe enough to
cause death.
CHI3L1 alone had excellent sensitivity (>90%) but poor
specificity (<70%) for predicting mortality in children with
severe malaria. Combining CHI3L1 with other host bio-
markers improved predictive accuracy, which has import-
ant practical implications in resource-poor health care
settings with limited availability of intensive care. Severe
malaria patients at higher risk of death could be prioritized
for referral and more intensive monitoring and supportive
Table 2 Performance of CHI3L1 alone and in combination for predicting mortality among children with severe malariaa
Markers Cut-pointb Sensitivity (%) Specificity (%) PLRc NLR PPV (%)d NPV (%)
CHI3L1 ≥179.1 ng/mL 91.3 (73.2-97.6) 67.5 (56.6-76.7) 2.8 (2.0-3.9) 0.13 (0.034-0.49) 14.5 (5.0-30.3) 99.2 (93.1-100)
CHI3L1, IP-10, sICAM-1 ≥2 points 91.3 (73.2-97.5) 83.8 (74.2-90.3) 5.6 (3.4-9.4) 0.10 (0.028-0.39) 25.4 (9.2-48.8) 99.4 (94.4-100)
CHI3L1, Ang-2, IP-10 ≥2 points 100 (85.7-100) 81.3 (71.3-88.3) 5.3 (3.4-8.4) – 24.4 (9.4-46.0) 100 (95.4-100)
CHI3L1, Ang-2, sICAM-1 ≥2 points 95.7 (79.0-99.2) 81.3 (71.3-88.3) 5.1 (3.2-8.1) 0.054 (0.008-0.37) 23.6 (8.6-45.7) 99.7 (94.8-100)
aAll parameters are presented with 95% CIs in parentheses. bCut-points were determined using the Youden Index (J = max[sensitivity + specificity – 1]). cPLR,
positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value; sICAM-1, soluble ICAM-1, Ang-2, angiopoietin-2.
dPPVs and NPVs were based on estimates that 5.7% of CM and SMA patients at Mulago hospital die of their malaria infection [34].
Figure 2 Human PBMCs produce CHI3L1 upon stimulation with
P. falciparum. PBMCs were exposed to medium alone, uninfected
red blood cells (RBCs; negative control), P. falciparum infected RBCs
(Pf), or LPS (positive control) for 8 and 24 hrs. (A) Chi3l1 mRNA was
assessed by quantitative real-time PCR, and (B) CHI3L1 concentration
in supernatants was measured by ELISA. Graphs represent pooled
data from at least 3 independent experiments using different PBMC
donors. Data are presented as medians with interquartile ranges.
*p < 0.05, Kruskal-Wallis test with Dunn’s post-tests.
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termine whether these measures could improve outcome.
Moreover, in clinical trials of adjunctive therapies for se-
vere malaria, a prognostic test could be used to stratify pa-
tients into risk categories, since treatment efficacy can
vary depending on risk of death [40]. While clinical and la-
boratory parameters have been associated with mortality
in severe malaria [41-43], predictive accuracy is not ideal.
A quantitative point-of-care biomarker panel based on
emerging technologies [44] could enable rapid, objective
assessment.
Prospective studies in multiple populations are required
to confirm the findings in this report. The current study
had some limitations, including small sample size and
non-consecutive sampling, possibly introducing selection
bias. Future studies should also evaluate whether common
childhood co-infections associated with elevated CHI3L1,
such as pneumonia and schistosomiasis [26,45], affect the
accuracy of CHI3L1 as a prognostic indicator in malaria
infection. CHI3L1 elevation alone is likely too non-specific
to identify retinopathy-positive CM, which approximates
“true” CM [46,47]. However, the prognostic ability of
CHI3L1 in combination with other host biomarkers
should be evaluated in this group, particularly as surrogate
markers for retinopathy are in development for use in
clinical settings [35,48].
Increased plasma CHI3L1 in severe and fatal human
malaria prompted examination of CHI3L1 in malaria
models. Plasmodium falciparum stimulated CHI3L1 pro-
duction by human PBMCs in vitro. Activated monocytes
were likely the main source of CHI3L1 in this system;
while CHI3L1 is not expressed by freshly isolated mono-
cytes, differentiation into macrophages – as might be trig-
gered by interaction with P. falciparum – induces its
transcription [49]. Additional cell types may have contrib-
uted to increased plasma CHI3L1 in P. berghei infection,
such as neutrophils, which are activated during malaria in-
fection [50,51] but excluded from PBMC preparations.
CHI3L1 expression in the brain was also increased during
P. berghei infection in mice susceptible to ECM, poten-
tially due to upregulated transcription in astrocytes [23,52]
or intravascular monocyte sequestration [11].
The precise pathways mediating CHI3L1 induction by
malaria remain undefined. Pro-inflammatory cytokines
Figure 3 CHI3L1 increases during experimental cerebral malaria but does not affect survival. (A) Plasma was collected over a time course
for P. berghei ANKA infection of C57BL/6 mice, and assayed for CHI3L1 by ELISA. **p < 0.01, ***p < 0.001 by Kruskal-Wallis test with Dunn’s
post-test. (B) On Days 0 and 5 of infection, Chi3l1 transcripts in brain were measured by quantitative real-time PCR and normalized to housekeeping
genes. *p < 0.05 by Mann–Whitney U test. (C) Four independent experiments were pooled to generate the survival curves shown (Chi3l1−/−, n = 65;
Wild-type littermates (WT), n = 51). The log-rank test was used to assess survival differences (p = 0.13). (D) Parasitaemia is represented as medians and
interquartile range. (E) Plasma was collected from wild-type and Chi3l1−/− mice on Day 4 of infection and assayed for cytokines. NS, not significant,
Mann Whitney U test. Cytokines were undetectable in all uninfected mice.
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tion [21,22]. Plasmodium falciparum components have
been shown to induce these cytokines via activation of
pattern recognition receptors such as TLRs [53-55]. Not-
ably, TLR2 and TLR4 agonists induce CHI3L1 in mono-
cytic cell lines [37,56], though it is unclear whether
direct TLR signalling or the resultant cytokine secretion
mediates the effect. To address this question, cyclohexi-
mide was added to the co-culture system, but this agent
has anti-malarial activity and abolished PBMC responses
(data not shown). Of note, hypoxia stimulated CHI3L1
production in a glioblastoma cell line [23], which pro-
motes cell survival [57]. This suggests that CHI3L1 up-
regulation in the brain in ECM in response to hypoxia
and/or cytokines could be a neuroprotective mechanism.However, in this study, there was no global effect of
Chi3l1 deletion on P. berghei infection of ECM-susceptible
mice. It was initially hypothesized that CHI3L1 would de-
crease pathological TH1 inflammation in ECM, and that,
similar to the Streptococcal pneumonia model, Chi3l1 dele-
tion would worsen outcome. In fact, Chi3l1 deletion failed
to alter measures of TH1 inflammation in ECM. This may
be due to differential pathway engagement: CHI3L1 exerted
its major effects in the pneumonia model by regulating the
NRLP3 inflammasome [28], while involvement of the clas-
sical NRLP3 inflammasome in ECM pathogenesis is doubt-
ful [58,59]. Alternatively, any worsening of outcome may
have been counterbalanced by beneficial effects of Chi3l1
deletion. CHI3L1 could theoretically promote pathological
inflammatory responses by supporting survival of immune
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http://www.malariajournal.com/content/13/1/279cells [27] or activating endothelial cells [60]. In the ECM
model, CD8+ T cells and monocytes accumulate in brain
microvasculature [39,61], where they secrete mediators
such as perforin that directly cause endothelial injury [62]
and cytokines that promote endothelial activation, parasite
sequestration, and vascular leak [10,38,63]. Multiple, com-
peting roles for CHI3L1 have also been observed in a
model of cigarette smoke exposure, in which CHI3L1 pro-
moted pathological inflammatory infiltrates yet also
protected lung epithelial cells from apoptosis [64].
Finally, it may simply be technically challenging to de-
tect worsened outcome in ECM-susceptible mice. There
are scant examples in the literature of single gene alter-
ations leading to earlier death in this model, and these
have been associated with more rapid parasite replication
[65]. It may be that a critical parasite burden is required to
initiate the central pathological pathways of ECM, and the
subsequent decline is so time-compressed that it is diffi-
cult to discern earlier onset of morbidity or mortality.
Conclusions
In Ugandan children with malaria, plasma levels of
CHI3L1 were elevated in severe disease and further
increased in those who subsequently died of infection.
In combination with other host biomarkers, CHI3L1
holds promise as a prognostic biomarker in severe
malaria infection; further studies are warranted to val-
idate this finding. Although deletion of Chi3l1 did
not alter key disease parameters or death in the P.
berghei model of ECM, these findings do not exclude
a role for CHI3L1 in human severe malaria because
of model limitations and, potentially, the multiplicity
of CHI3L1 functions.
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